Frost & Sullivan
MARCH 30, 2021
Pharmaceuticals and biotechnology, IVD, advanced medical technologies, medical imaging and informatics, and digital health expected to hit over $2.6 trillion by 2025. trillion by 2025, growing at a compound annual growth rate of 6.3%. Santa Clara, Calif.
Frost & Sullivan
MARCH 30, 2021
Pharmaceuticals and biotechnology, IVD, advanced medical technologies, medical imaging and informatics, and digital health expected to hit over $2.6 trillion by 2025. trillion by 2025, growing at a compound annual growth rate of 6.3%. Santa Clara, Calif.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
LaVoie Health Science Blog
SEPTEMBER 20, 2024
Here are the three insights I learned this summer and what I will take back to Norway as I complete my master’s degree: The complexity of biotechnology and pharmaceuticals I think most people agree that biotechnology and pharmaceuticals are complex industries, rooted in “hard science” technology.
Frost & Sullivan
SEPTEMBER 8, 2022
Further, the need for antimicrobial technology as a macro form of COVID-19 prevention and to reduce the risk of rapid spreading will raise the global government interest in antimicrobic surface, biofilm, and coating adoption in building, construction, and food packaging by 2025. For further information on this analysis, please click here.
LaVoie Health Science Blog
DECEMBER 16, 2024
Looking ahead to 2025, professionals worldwide are eagerly gearing up for one of the most anticipated events in the financial calendarthe J.P. Morgan 2025 experience. As you prepare for 2025, stay informed about the latest advancements in these fields to ensure your conversations and engagements are cutting edge.
Frost & Sullivan
APRIL 3, 2024
Fuelling Growth: Strategic Investments, Acquisitions, and Expansions Samsung Biologics unveiled plans to expand capacity and geographic reach by initiating the construction of Bio Campus II with a $6 billion investment scheduled to begin operations in 2025 while completing its CGMP antibody-drug conjugate manufacturing facility within 2024.
Jake Jorgovan
FEBRUARY 2, 2025
Updated: February 2025 "Science and everyday life cannot and should not be separated." - Rosalind Franklin It should go without saying, but life science can be quite complicated. The company addresses the challenges faced by pharmaceutical, medical device, biotechnology, and diagnostic firms.
Expert insights. Personalized for you.
98 
Let's personalize your content